Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04047121 · ClinicalTrials.gov registry record
A Study to Evaluate Patient Characteristics and Treatment Patterns Among Rheumatoid Arthritis Patients
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 1,349
- Enrollment target
NCT04047121: Completed study, sponsored by Pfizer.
NCT04047121 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 1,349 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04047121 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 1,349 participants
- Enrollment target
Study Summary
This is a retrospective cohort study to evaluate patient characteristics, treatment patterns including a 6-factor effectiveness proxy measure, health care resource use and associated costs among Rheumatoid Arthritis patients initiating treatment comparator groups of interest between January 2014 and September 2016 across three United States insurance claims databases.
Primary Outcome
Persistent with the index medication was defined as not having a gap in the therapy of at least 60 days between prescription fill dates and their administration. Index medications were tofacitinib, adalimumab or etanercept.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,349 participants |
| Start Date | 2019-05-20 |
| Est. Completion | 2019-10-21 |
What the finished NCT04047121 record still lists
NCT04047121 is an observational study that tracks outcomes without assigning an intervention. Its 1,349 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT04047121 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04047121 about?
NCT04047121 is a clinical study titled "A Study to Evaluate Patient Characteristics and Treatment Patterns Among Rheumatoid Arthritis Patients". This is a retrospective cohort study to evaluate patient characteristics, treatment patterns including a 6-factor effectiveness proxy measure, health care resource use and associated costs among Rheumatoid Arthritis patients initiating treatment comparator groups of interest between January 2014 and...
What is the current status of trial NCT04047121?
This trial is currently completed. The enrollment target is 1,349 participants. The study started on 2019-05-20. Estimated completion is 2019-10-21.
Who is sponsoring clinical trial NCT04047121?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06318169 · 1,350 participants · Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- NCT06605404 · 1,350 participants
Pan-tumor MRD Study
- NCT06806163 · 1,350 participants · NA
Machine-Learning Prediction and Reducing Overdoses With EHR Nudges
- NCT06731608 · 1,344 participants · NA
OsteoPorotic fracTure preventION System (OPTIONS) Research Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI